This Cooperative Agreement award from the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310) provides $555,283 to Duke University to identify and optimize medical countermeasures for phosgene inhalation injuries. The research aims to: 1) Screen the efficacy of renin-angiotensin-aldosterone system (RAAS) modulators and soluble epoxide hydrolase inhibitors (sEHIs) in mouse models of phosgene gas-induced lung injury; 2) Determine the pharmacokinetics of lead drug candidates and test efficacy in a 48-hour swine model of phosgene-induced lung injury; and 3) Evaluate the therapeutic efficacy of lead candidates in a 28-day swine model of phosgene-induced lung injury. Successful completion of this project will provide critical information to develop targeted treatments for phosgene gas-induced lung injuries, a significant unmet medical need, and prepare for further biomedical research and regulatory approvals.
Generated 7/1/25, 1:50 AM